Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) (NATHAN1)

Meda Pharmaceuticals

Status and phase

Completed

Phase 3

Conditions

Diabetic Polyneuropathy

Treatments

Drug: Thioctic Acid

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00977483

NATHAN1

D-20557/9353000001

D-20557-3011

Details and patient eligibility

About

To assess clinical efficacy and safety of long-term orally administered thioctic acid in the treatment of diabetic polyneuropathy.

Full description

Stage 1 or 2a diabetic (poly)neuropathy (DNP) (Appendix 3) in patients with diabetes mellitus (type I or II); neuropathy impairment score of the lower limbs, enlarged by 7 objective items (NISLL+7) ≥ 97.5 percentile (corresponding to 4.43 score points); total symptoms score of the feet (TSSfeet) ≤ 5.

Enrollment

460 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed Informed Consent. Patients must have willingness and complete competence to cooperate and language barriers must not preclude adequate understanding
Diabetes mellitus (Type I or II), as defined by the American Diabetes Association 1997, lasting > 1 year
Males or females 18 to 64 years (older patients are excluded because of age-related changes in reflexes, quantitative sensory testing endpoints, and nerve conduction endpoints)
Patient must have a symmetric sensory-motor peripheral polyneuropathy attributable to diabetes mellitus following a thorough evaluation for other causes of neuropathy determined by performing complete medical and neurological examinations including physical and neurological history, history of medications, history of exposure to other toxins, and laboratory studies
Severity of diabetic polyneuropathy must be Stage 1 or 2a
Insulin regimen, weight, diet, and activity level must be relatively stable in the opinion of the investigator (for example, HbA1C must not vary by more than ± 2 Vol.% within 6 months preceding the study i.e. if the index measure = 10% the range would be 8-12%)
NIS[LL]+7 tests ≥ 97.5 percentiles (corresponding to 4.43 transformed score points)
NIS[LL] ≥ 2 points (NIS[LL] is based on questions 17-24, 28, 29, 34, 35, and 37 of the NIS)
One of the following:
- an abnormality of nerve conduction attributes in two separate nerves, i.e. ≥99th percentile for DL or ≤1st percentile for NCV or amplitude or
- an abnormality of HRDB, i.e. ≤ 1st percentile
TSS (feet) ≤5
Females must either be surgically sterilised (tubal ligation, bilateral oophorectomy, or hysterectomy) or at least 1 year postmenopausal or practicing an acceptable method of contraception, including oral contraceptives with a stable regimen for at least two months, depo-medroxyprogesterone, a barrier method alone (diaphragm, condoms, or contraceptive sponge with spermicidals), or an IUD that has been in place for at least two months

Exclusion criteria

Patients with proximal asymmetric neuropathy, cranial neuropathies, truncal radiculopathy, pan dysautonomia, diabetic plexopathies, or acute or active mononeuropathies (including cranial neuropathies, post-herpetic neuralgias, etc.), the presence of which might obscure accurate assessment of severity of the diabetic polyneuropathy under assessment, with the exception of carpal tunnel syndrome (CTS) or tardy ulnar neuropathy (TUN) or both
Neuropathy of any cause other than diabetes mellitus which might interfere with the assessment of the severity of dPNP Other neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms or test abnormality which might interfere with the assessment of the severity of dPNP Myopathy of any cause which might interfere with the assessment of the severity of dPNP
Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers or limb ischemia
Patients with a history of ophthalmological findings suggesting a high risk for visual loss i.e., significant maculopathy or proliferative retinopathy
Psychiatric, psychological, or behavioural symptoms that would interfere with the patient's ability to participate in the trial
Patients with any active neoplastic disease except basal cell carcinoma
Patients with atrial fibrillation unless controlled and stabilised by medication (changed to this criterion by Amendment 1)
Patients with clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or endocrine disease (other than diabetes) that may confound interpretation of the study results or prevent the patient from completing the study
Patients who have had organ transplants of any kind
Patients with significant hepatic or renal disease (ASAT or ALAT >2 times normal, serum creatinine >1.8 mg/dL (>159 µmol/l) for males or >1.6 mg/dL (>141 µmol/l) for females)
Patients with a recent history (within last 12 months) of drug or alcohol abuse
Use of any investigational drug within the last 6 months
History of severe or anaphylactic reaction to multiple drugs, sulfur products, or biologic products (changed to this criterion by Amendment 1)
Ketoacidosis or hypoglycaemia within last 3 months resulting in hospital admission
Antioxidant therapy (vitamins E > 400IU, C > 200mg, and beta-Carotene > 30mg) or pentoxyphylline within last 1 month before start of trial
Use of evening primrose oil or any other gamma-linolenic acid containing substance within the last 3 months
Use of thioctic acid > 50mg/day within last 3 months
History of use of medications or vitamins known to cause peripheral neuropathy including but not limited to use of phenytoin or carbamazepine over 15 or more years, or use of pyridoxine > 100mg/d within the past 12 months
Bilateral sural nerve biopsies
Existing foot ulcers
Pregnant or lactating females
Continued use of medications listed in protocol 6.3.3 (first paragraph)
Medication non-compliance (deviation of more than ±10% of dosages to be taken (1 tablet/day))